Next Article in Journal
Polycomb Assemblies Multitask to Regulate Transcription
Next Article in Special Issue
Application of the High-Throughput TAB-Array for the Discovery of Novel 5-Hydroxymethylcytosine Biomarkers in Pancreatic Ductal Adenocarcinoma
Previous Article in Journal
Integrating Signals from Sperm Methylome Analysis and Genome-Wide Association Study for a Better Understanding of Male Fertility in Cattle
Open AccessArticle

Disruption of Broad Epigenetic Domains in PDAC Cells by HAT Inhibitors

Biomedical and Health Sciences Department, University of Vermont, Burlington, VT 05405, USA
Cellular Molecular Biomedical Sciences Program, University of Vermont, Burlington, VT 05405, USA
Biochemistry, University of Vermont, Burlington, VT 05405, USA
The University of Vermont Cancer Center, Burlington, VT 05405, USA
Department of Molecular Medicine, University of Texas Health Science Center, San Antonio, TX 78229, USA
Author to whom correspondence should be addressed.
Epigenomes 2019, 3(2), 11;
Received: 20 April 2019 / Revised: 16 May 2019 / Accepted: 29 May 2019 / Published: 2 June 2019
The spreading of epigenetic domains has emerged as a distinguishing epigenomic phenotype for diverse cell types. In particular, clusters of H3K27ac- and H3K4me3-marked elements, referred to as super-enhancers, and broad H3K4me3 domains, respectively, have been linked to cell identity and disease states. Here, we characterized the broad domains from different pancreatic ductal adenocarcinoma (PDAC) cell lines that represent distinct histological grades. Our integrative genomic analysis found that human derived cell line models for distinct PDAC grades exhibit characteristic broad epigenetic features associated with gene expression patterns that are predictive of patient prognosis and provide insight into pancreatic cancer cell identity. In particular, we find that genes marked by overlapping Low-Grade broad domains correspond to an epithelial phenotype and hold potential as markers for patient stratification. We further utilize ChIP-seq to compare the effects of histone acetyltransferase (HAT) inhibitors to detect global changes in histone acetylation and methylation levels. We found that HAT inhibitors impact certain broad domains of pancreatic cancer cells. Overall, our results reveal potential roles for broad domains in cells from distinct PDAC grades and demonstrate the plasticity of particular broad epigenomic domains to epigenetic inhibitors. View Full-Text
Keywords: super-enhancers; epigenomics; pancreatic cancer super-enhancers; epigenomics; pancreatic cancer
Show Figures

Graphical abstract

MDPI and ACS Style

Gerrard, D.L.; Boyd, J.R.; Stein, G.S.; Jin, V.X.; Frietze, S. Disruption of Broad Epigenetic Domains in PDAC Cells by HAT Inhibitors. Epigenomes 2019, 3, 11.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop